Potential measures to facilitate the productions of activepharmaceutical ingredients (APIs)

whitePaper | September 16, 2022

T wice a year, we survey the cell and gene therapy landscape and ARM’s initiatives to advance the sector and provide an update to our members.

whitePaper | December 14, 2022

When the regulatory hammer came down on pharmaceutical and life sciences (PLS) companies in the 2010s, it introduced new complexities for these businesses.

whitePaper | October 27, 2022

In today’s evolving, value-based environment for specialty drugs, hightouch services that enhance patient outcomes are playing an increasingly important role in market access and patient care delivery

whitePaper | June 21, 2022

nduced-proximity targeted protein degradation (TPD) is a ground-breaking strategy in drug discovery that has emerged during the last decade.

whitePaper | June 5, 2022

Although our growing scientific understanding and improvements made in medical technology lead to significant advances in human health and wellbeing, many therapy strategies remain insufficient,

whitePaper | April 12, 2022

The level of pharmaceutical expenditure is closely watched and often commented upon, but the composition of that expenditure and its dynamics are not as well understood.